Valuation: Imunon, Inc.

Market Cap 8.24M 7.22M 6.69M 6.16M 11.64M 788M 11.87M 79.74M 31.28M 387M 30.93M 30.25M 1.34B P/E 2026 *
-0.63x
P/E 2027 * -0.86x
Enterprise Value 8.24M 7.22M 6.69M 6.16M 11.64M 788M 11.87M 79.74M 31.28M 387M 30.93M 30.25M 1.34B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
94.92%
Yield 2026 *
-
Yield 2027 * -
1 day-2.97%
1 week-1.01%
Current month+10.11%
1 month-2.97%
3 months-33.78%
6 months-48.42%
Current year-48.56%
1 week 1.9
Extreme 1.9
2.15
1 month 1.7
Extreme 1.7
2.18
Current year 1.7
Extreme 1.7
4.2
1 year 1.7
Extreme 1.7
10.4
3 years 1.7
Extreme 1.7
47.61
5 years 1.7
Extreme 1.7
244.56
10 years 1.7
Extreme 1.7
3,834.81
Manager TitleAgeSince
Chief Executive Officer 56 2024-05-12
Director of Finance/CFO 53 2026-06-30
Chief Tech/Sci/R&D Officer 73 2025-02-17
Director TitleAgeSince
Chairman 75 2014-10-06
Director/Board Member 75 2011-07-07
Director/Board Member 76 2015-12-14
Date Insider Type Main position Quantity % Market Cap.
07-05Sell

General Counsel

-920 0.0365%
07-01Free

Chief Executive Officer

2,534 0.1005%
07-01Free

Chief Technology Officer

1,308 0.0519%
Change 5-day change 1-year change 3-year change Capi.($)
-2.97%-1.01%-75.17%-88.07% 8.24M
-2.48%-2.22%+55.85%+79.12% 53.54B
0.00%-6.45%+55.89%+127.49% 54.18B
-5.60%-2.15%+11.16%+420.46% 23.66B
-1.55%-4.11%-20.21%-17.75% 22.78B
+2.36%+3.86%+42.80%-6.60% 19.54B
-1.09%+0.03%+38.27%-27.73% 17.82B
-2.72%-4.04%+187.08%+362.09% 16.01B
-1.15%-3.07%+45.33%+654.85% 15.37B
-0.81%+0.92%+24.92%+189.61% 14.09B
Average -1.61%-1.61%+36.59%+169.34% 23.7B
Weighted average by Cap. -1.47%-1.99%+48.03%+162.85%

Financials

2026 *2027 *
Net sales - -
Net income -16.41M -14.39M -13.33M -12.26M -23.2M -1.57B -23.65M -159M -62.31M -771M -61.61M -60.27M -2.66B -23.33M -20.46M -18.95M -17.44M -32.98M -2.23B -33.62M -226M -88.58M -1.1B -87.6M -85.68M -3.79B
Net Debt - -
Logo Imunon, Inc.
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Employees
20
Date Price Change Volume
26-07-13 US$1.960 -2.97% 25,228
26-07-10 US$2.020 +0.50% 13,496
26-07-09 US$2.010 -2.43% 27,141
26-07-08 US$2.060 +5.64% 43,193
26-07-07 US$1.950 -1.52% 25,962
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.960USD
Average target price
17.00USD
Spread / Average Target
+767.35%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMNN Stock